Abstract:Angewandte Chemie International EditionVolume 49, Issue 21 p. 3649-3652 Communication A Left-Handed Solution to Peptide Inhibition of the p53–MDM2 Interaction† Min Liu Dr., Min Liu Dr. Institute of Human Virology, University of Maryland School of Medicine, 725 W. Lombard St., Baltimore, MD 21201 (USA) The First Affiliated Hospital, Xi'an Jiaotong University School of Medicine (China) These authors contributed equally to this work.Search for more papers by this authorMarzena Pazgier Dr., Marzena Pazgier Dr. Institute of Human Virology, University of Maryland School of Medicine, 725 W. Lombard St., Baltimore, MD 21201 (USA) These authors contributed equally to this work.Search for more papers by this authorChangqing Li Dr., Changqing Li Dr. Institute of Human Virology, University of Maryland School of Medicine, 725 W. Lombard St., Baltimore, MD 21201 (USA) These authors contributed equally to this work.Search for more papers by this authorWeirong Yuan, Weirong Yuan Institute of Human Virology, University of Maryland School of Medicine, 725 W. Lombard St., Baltimore, MD 21201 (USA)Search for more papers by this authorChong Li, Chong Li Institute of Human Virology, University of Maryland School of Medicine, 725 W. Lombard St., Baltimore, MD 21201 (USA)Search for more papers by this authorWuyuan Lu Prof., Wuyuan Lu Prof. [email protected] Institute of Human Virology, University of Maryland School of Medicine, 725 W. Lombard St., Baltimore, MD 21201 (USA)Search for more papers by this author Min Liu Dr., Min Liu Dr. Institute of Human Virology, University of Maryland School of Medicine, 725 W. Lombard St., Baltimore, MD 21201 (USA) The First Affiliated Hospital, Xi'an Jiaotong University School of Medicine (China) These authors contributed equally to this work.Search for more papers by this authorMarzena Pazgier Dr., Marzena Pazgier Dr. Institute of Human Virology, University of Maryland School of Medicine, 725 W. Lombard St., Baltimore, MD 21201 (USA) These authors contributed equally to this work.Search for more papers by this authorChangqing Li Dr., Changqing Li Dr. Institute of Human Virology, University of Maryland School of Medicine, 725 W. Lombard St., Baltimore, MD 21201 (USA) These authors contributed equally to this work.Search for more papers by this authorWeirong Yuan, Weirong Yuan Institute of Human Virology, University of Maryland School of Medicine, 725 W. Lombard St., Baltimore, MD 21201 (USA)Search for more papers by this authorChong Li, Chong Li Institute of Human Virology, University of Maryland School of Medicine, 725 W. Lombard St., Baltimore, MD 21201 (USA)Search for more papers by this authorWuyuan Lu Prof., Wuyuan Lu Prof. [email protected] Institute of Human Virology, University of Maryland School of Medicine, 725 W. Lombard St., Baltimore, MD 21201 (USA)Search for more papers by this author First published: 06 May 2010 https://doi.org/10.1002/anie.201000329Citations: 73 † This work was supported in part by a Research Scholar Grant CDD112858 from the American Cancer Society and the National Institutes of Health Grants AI072732 and AI061482 (to W.L.). p53=tumor suppressor protein 53; MDM2=murine double minute 2 protein. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Graphical Abstract Throwing tumors a left-hook punch: The oncoprotein MDM2 negatively regulates the activity and stability of the tumor suppressor protein p53, and is an important molecular target for anticancer therapy. Mirror-image phage display identified a high-affinity D-peptide ligand of MDM2 (see structure) that could be developed into a potent and protease-resistant p53 activator with potential antitumor activity. References 1 1aR. E. Moellering, M. Cornejo, T. N. Davis, C. Del Bianco, J. C. Aster, S. C. Blacklow, A. L. Kung, D. G. Gilliland, G. L. Verdine, J. E. Bradner, Nature 2009, 462, 182; 1bL. D. Walensky, A. L. Kung, I. Escher, T. J. Malia, S. Barbuto, R. D. Wright, G. Wagner, G. L. Verdine, S. J. Korsmeyer, Science 2004, 305, 1466. 2M. R. Arkin, J. A. Wells, Nat. Rev. Drug Discovery 2004, 3, 301. 3 3aT. N. Schumacher, L. M. Mayr, D. L. Minor, Jr., M. A. Milhollen, M. W. Burgess, P. S. Kim, Science 1996, 271, 1854; 3bD. M. Eckert, V. N. Malashkevich, L. H. Hong, P. A. Carr, P. S. Kim, Cell 1999, 99, 103. 4 4aP. E. Dawson, T. W. Muir, I. Clark-Lewis, S. B. Kent, Science 1994, 266, 776; 4bS. B. Kent, Chem. Soc. Rev. 2009, 38, 338. 5 5aC. J. Brown, S. Lain, C. S. Verma, A. R. Fersht, D. P. Lane, Nat. Rev. Cancer 2009, 9, 862; 5bS. Shangary, D. Qin, D. McEachern, M. Liu, R. S. Miller, S. Qiu, Z. Nikolovska-Coleska, K. Ding, G. Wang, J. Chen, D. Bernard, J. Zhang, Y. Lu, Q. Gu, R. B. Shah, K. J. Pienta, X. Ling, S. Kang, M. Guo, Y. Sun, D. Yang, S. Wang, Proc. Natl. Acad. Sci. USA 2008, 105, 3933; 5cL. T. Vassilev, B. T. Vu, B. Graves, D. Carvajal, F. Podlaski, Z. Filipovic, N. Kong, U. Kammlott, C. Lukacs, C. Klein, N. Fotouhi, E. A. Liu, Science 2004, 303, 844. 6 6aK. H. Vousden, D. P. Lane, Nat. Rev. Mol. Cell Biol. 2007, 8, 275; 6bF. Toledo, G. M. Wahl, Nat. Rev. Cancer 2006, 6, 909. 7 7aP. H. Kussie, S. Gorina, V. Marechal, B. Elenbaas, J. Moreau, A. J. Levine, N. P. Pavletich, Science 1996, 274, 948; 7bO. Schon, A. Friedler, M. Bycroft, S. M. Freund, A. R. Fersht, J. Mol. Biol. 2002, 323, 491. 8A. Böttger, V. Bottger, C. Garcia-Echeverria, P. Chene, H. K. Hochkeppel, W. Sampson, K. Ang, S. F. Howard, S. M. Picksley, D. P. Lane, J. Mol. Biol. 1997, 269, 744. 9M. Pazgier, M. Liu, G. Zou, W. Yuan, C. Li, J. Li, J. Monbo, D. Zella, S. G. Tarasov, W. Lu, Proc. Natl. Acad. Sci. USA 2009, 106, 4665. 10C. Li, M. Pazgier, M. Liu, W. Y. Lu, W. Lu, Angew. Chem. 2009, 121, 8868; Angew. Chem. Int. Ed. 2009, 48, 8712. 11J. C. Marine, M. A. Dyer, A. G. Jochemsen, J. Cell Sci. 2007, 120, 371. 12C. E. Schafmeister, J. Po, G. L. Verdine, J. Am. Chem. Soc. 2000, 122, 5891. 13F. Bernal, A. F. Tyler, S. J. Korsmeyer, L. D. Walensky, G. L. Verdine, J. Am. Chem. Soc. 2007, 129, 2456. 14J. K. Murray, S. H. Gellman, Biopolymers 2007, 88, 657. 15 15aR. Fasan, R. L. Dias, K. Moehle, O. Zerbe, J. W. Vrijbloed, D. Obrecht, J. A. Robinson, Angew. Chem. 2004, 116, 2161; Angew. Chem. Int. Ed. 2004, 43, 2109; 15bJ. A. Robinson, Acc. Chem. Res. 2008, 41, 1278. 16 16aJ. A. Kritzer, R. Zutshi, M. Cheah, F. A. Ran, R. Webman, T. M. Wongjirad, A. Schepartz, ChemBioChem 2006, 7, 29; 16bB. Hu, D. M. Gilkes, J. Chen, Cancer Res. 2007, 67, 8810; 16cC. Li, M. Liu, J. Monbo, G. Zou, W. Yuan, D. Zella, W. Y. Lu, W. Lu, J. Am. Chem. Soc. 2008, 130, 13546. 17M. Schnolzer, P. Alewood, A. Jones, D. Alewood, S. B. Kent, Int. J. Pept. Protein Res. 1992, 40, 180. 18C. N. Pace, F. Vajdos, L. Fee, G. Grimsley, T. Gray, Protein Sci. 1995, 4, 2411. Citing Literature Supporting Information Detailed facts of importance to specialist readers are published as ”Supporting Information”. Such documents are peer-reviewed, but not copy-edited or typeset. They are made available as submitted by the authors. Filename Description anie_201000329_sm_miscellaneous_information.pdf4.5 MB miscellaneous_information Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article. Volume49, Issue21May 10, 2010Pages 3649-3652 ReferencesRelatedInformation

Robust Generation of Lead Compounds for Protein-Protein Interactions by Computational and MCR Chemistry: P53/hdm2 Antagonists.

Computational-based drug design of novel small molecules targeting p53-MDMX interaction

Transient Protein States in Designing Inhibitors of the MDM2-p53 Interaction

Exhaustive fluorine scanning toward potent p53-Mdm2 antagonists.

Altering relative metal-binding affinities in multifunctional Metallochaperones for mutant p53 reactivation

Structure-Based Design of Potent and Orally Active Isoindolinone Inhibitors of MDM2-p53 Protein–Protein Interaction

Small Molecule Inhibitors of the P53-Mdm2

Molecular Modeling and Molecular Dynamics Simulation Studies on Pyrrolopyrimidine-Based Α-Helix Mimetic As Dual Inhibitors of MDM2 and MDMX

A Left‐Handed Solution to Peptide Inhibition of the P53–mdm2 Interaction

Chemical Perturbation of Oncogenic Protein Folding: from the Prediction of Locally Unstable Structures to the Design of Disruptors of Hsp90-Client Interactions

Integrated virtual screening and molecular dynamics simulation revealed promising drug candidates of p53-MDM2 interaction

Apamin As a Template for Structure‐Based Rational Design of Potent Peptide Activators of P53

Directed Evolution of Orthogonal Ligand Specificity in a Single Scaffold

Design of ultrahigh-affinity and dual-specificity peptide antagonists of MDM2 and MDMX for P53 activation and tumor suppression

Abstract 4533: in Vivo Activation of the P53 Pathway Leading to Tumor Regression by a Novel and Potent HDM2 Antagonist SCH 1450206

Abstract 4534: A Novel and Potent Small Molecule Antagonist of HDM2, SCH 1450206, Activates the P53 Pathway with Mechanism-Based Activity

Synthesis, crystal structure, Hirshfeld surface, computational and biological studies of spiro-oxindole derivatives as MDM2-p53 inhibitors

Design and synthesis of a C7-aryl piperlongumine derivative with potent antimicrotubule and mutant p53-reactivating properties

Novel Allosteric Mechanism of Dual p53/MDM2 and p53/MDM4 Inhibition by a Small Molecule

Discovery of spirooxindole–ferrocene hybrids as novel MDM2 inhibitors

Probing the origin of structural stability of single and double stapled p53 peptide analogs bound to MDM2